Clinical trials: Anti Cholinergics
Asthma
Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)
Primary objective The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory…
- Trial name
- ELITRA (NCT02296411)
- Testing
- CHF 5259 12.5 µg + Qvar
- Where
- 28 sites in Bulgaria, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Parkinson's Disease, Neurogenic Bladder
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
The basic nerve deficit of Parkinson's disease (PD) leads to lower urinary tract symptoms of frequency, urgency and urge urinary incontinence. Lower urinary tract symptoms tend to occur at more advanced stages of PD.
- Conditions
- Parkinson's Disease, Neurogenic Bladder, Urinary Incontinence, Clostridium Botulinum Toxin Adverse Reaction
- Trial name
- NCT01421719
- Testing
- Cystoscopic injection of Botox into the urinary bladder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Urticaria
An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)
This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with chronic urticaria. The primary hypothesis is that the efficacy of desloratadine 10 mg and 5 mg is superior to placebo as…
- Trial name
- NCT01916967
- Testing
- Desloratadine
- Volunteers
- 239 people
- Sponsor
- Organon and Co
Mental Competency, Urinary Bladder, Overactive
The Effect of Anticholinergics on Cognitive Function in the Elderly
Anticholinergic medication is used to treat overactive bladder (OAB). A known side effect of this medication is cognitive dysfunction.
- Conditions
- Mental Competency, Urinary Bladder, Overactive, Cognitive Function
- Trial name
- ACE (NCT01922115)
- Testing
- Trospium Chloride
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Atropine Bioequivalence
Sublingual Atropine Bioequivalence by Route of Administration (SABER)
A randomized, two-period, two-sequence, crossover study to assess the bioequivalence, bioavailability, and pharmacokinetics (PK) of a single dose of atropine administered sublingually (SL) or intramuscularly (IM) in healthy adult…
- Trial name
- SABER (NCT06366087)
- Testing
- Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Anticholinergics Toxicity
Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
Overdose of xenobiotics (antihistamines, antipsychotics, or Jimson Weed) with resulting antimuscarinic toxidrome is a common scenario in medical toxicology.
- Trial name
- TAAT (NCT03090620)
- Testing
- Physostigmine, Lorazepam
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Chronic Spinal Cord Injury, Neurogenic Bladder
Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
The purpose of this study is to determine the efficacy of home transcutaneous tibial nerve stimulation (TTNS) in spinal cord injury(SCI) and to determine the impact on quality of life using TTNS at home
- Trial name
- TTNS-RCT (NCT04074616)
- Testing
- High Dose, Low dose
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center, Houston
Asthma, Depression
Defining and Treating Depression-related Asthma
Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less…
- Conditions
- Asthma, Depression, Childhood Asthma
- Trial name
- NCT04617015
- Testing
- Ipratropium Bromide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- State University of New York at Buffalo
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113373 (NCT01313650)
- Testing
- 62.5/25mcg, 62.5mcg, 25mcg
- Where
- 165 sites in United States, Bulgaria and 11 more
- Volunteers
- 1,538 people
- Sponsor
- GlaxoSmithKline
Urinary Incontinence, Urge
Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy
This study is randomized controlled trial in which urgency incontinent women (approximately 150-160) will be randomized to hypnotherapy or pharmacotherapy and evaluated at months 2, 6 \&12 Hypotheses: Among patients with urgency…
- Trial name
- Hyp-hOP (NCT01829425)
- Testing
- Anticholinergic medications, Hypnotherapy
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Pulmonary Disease, Chronic Obstructive
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
- Trial name
- NCT00950807
- Testing
- Tiotropium, GSK573179
- Where
- 19 sites in United States, Germany
- Volunteers
- 176 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population
The objective of this study was to examine COPD-related outcomes for patients with comorbid depression/anxiety who are on combination fluticasone propionate/salmeterol xinafoate compared to those receiving anticholinergics.
- Trial name
- NCT01337336
- Testing
- fluticasone propionate/salmeterol xinafoate, Anticholinergics
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Cognition
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.
- Trial name
- SENIOR (NCT01126424)
- Testing
- Solifenacin, Oxybutynin
- Where
- 3 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
COPD
Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
Preliminary information from our laboratory indicated that even patients with milder chronic obstructive pulmonary disease (COPD) can have significant physiological derangements which become more pronounced during exercise…
- Trial name
- NCT01491802
- Testing
- LAMA/LABA, LAMA
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Queen's University
Depression, Major Depressive Disorder
A Trial of AXS-05 in Patients With Major Depressive Disorder
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
- Trial name
- GEMINI (NCT04019704)
- Testing
- AXS-05
- Where
- 43 sites in United States
- Volunteers
- 327 people
- Sponsor
- Axsome Therapeutics, Inc.
Length of Stay, Anti Cholinergics
Anticholinergic Risk Scale and Resource Use After Elective Noncardiac Surgery
This study investigates the association of preoperative anticholinergic medication exposure with healthcare resource utilization in a population-based sample of older patients enrolled in a universal pharmacare program
- Conditions
- Length of Stay, Anti Cholinergics, Surgical Procedure, Operative, Aged
- Trial name
- NCT03151616
- Testing
- anticholinergic risk scale
- Where
- Canada
- Volunteers
- 244,976 people
- Sponsor
- Ottawa Hospital Research Institute
Aging, Benzodiazepine Sedative Adverse Reaction
NUDGE-EHR Replication Trial at Mass General Brigham
Prescribing of potentially unsafe medications for older adults is extremely common; benzodiazepines and sedative hypnotics are, for example, key drug classes frequently implicated in adverse health consequences for vulnerable…
- Conditions
- Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction, Adverse Drug Event
- Trial name
- NUDGE-EHR (NCT05538065)
- Testing
- Follow-up booster Alert, Pre-commitment, Enhanced Alert
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Brigham and Women's Hospital
Perennial Allergic Rhinitis
A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)
This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with perennial allergic rhinitis.
- Trial name
- NCT01918033
- Testing
- Desloratadine 5 mg
- Volunteers
- 608 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline